Orum Therapeutics Usa, Inc.
🇺🇸United States
Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors
Phase 1
Terminated
- Conditions
- HER2-positive Breast CancerHER-2 Protein OverexpressionHER-2 Gene AmplificationHER2 Gene Mutation
- Interventions
- First Posted Date
- 2022-08-23
- Last Posted Date
- 2025-07-04
- Lead Sponsor
- Orum Therapeutics USA, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT05511844
- Locations
- 🇺🇸
University of Alabama Birmingham, Birmingham, Alabama, United States
🇺🇸University of California - Los Angeles, Los Angeles, California, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
News
No news found